| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed172dc5d55f7c1786dfc74ddce6a5ef |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f9e355875a67c6dfe05a12498885939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e89e538d82e9488e7a5cd9abd39b2001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14e4c42eaed87dafe378520e2b87a621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_286a536f1ffcb66f8e1a68c40bd2913a |
| publicationDate |
2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021292755-A1 |
| titleOfInvention |
Novel double-stranded oligonucleotides for the treatment of cancer |
| abstract |
Disclosed is a double-stranded oligonucleotide for the use thereof in the prevention and/or treatment of cancer, in association with a therapy that causes damage to DNA or prevents the repair thereof. Also disclosed is a double-stranded oligonucleotide for the use thereof in the prevention and/or treatment of cancer, with the exception of androgen-dependent prostate cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115025216-A |
| priorityDate |
2016-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |